Clovis Oncology

CLVS NASDAQ
5.95
+0.06
+1.02%
After Hours: 5.95 0 0.00% 17:45 08/23 EDT
Open
5.85
Prev Close
5.89
High
6.10
Low
5.81
Volume
1.99M
Avg Vol (3M)
2.87M
52 Week High
37.21
52 Week Low
4.980
% Turnover
3.65%
Market Cap
325.21M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Clovis Oncology CLVS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
MORE >

Recently

Name
Price
%Change